Author

Lourdes Encinas

GlaxoSmithKline (Spain)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2

Frequent Co-Authors

Adolfo Garcia-Perez· 1 shared Alasdair Smith· 1 shared Alfonso Mendoza-LosanaiD· 1 shared Alice DawsoniD· 1 shared Beatriz BaragañaiD· 1 shared Chimed Jansen· 1 shared Curtis A. EngelhartiD· 1 shared David Barros-AguirreiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Adolfo Garcia-Perez

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Design and development of lysyl tRNA synthetase inhibitors, for the treatment of tuberculosis

Susan H. Davis, Michael Mathieson, Kirsteen I. Buchanan, Alice Dawson, Alasdair Smith, Mattia Cocco, Fábio K. Tamaki, John M. Post, Beatriz Baragaña, Chimed Jansen, Michael Kiczun, Fabio Zuccotto, Gavin Wood, Paul Scullion, Peter C. Ray, , Laura A. T. Cleghorn

The paper describes the development of lysyl tRNA synthetase inhibitors for tuberculosis treatment, optimizing compounds for preclinical and potential clinical use.

Journal of Medicinal Chemistry · Aug 1, 2025Peer-reviewedMicrobiology

Direct inhibitors of InhA with efficacy similar or superior to isoniazid in novel drug regimens for tuberculosis

Lourdes Encinas, Si-Yang Li, Joaquin Rullas-Trincado, Rokeya Tasneen, Sandeep Tyagi, Heena Soni, Adolfo Garcia-Perez, Jin Lee, del Rio Rubén González, Jaime De Mercado, Verónica Sousa, Izidor Sosič, Stanislav Gobec, Alfonso Mendoza-Losana, Paul J. Converse, , Eric L. Nuermberger

This study evaluates direct inhibitors of InhA (DIIs) for tuberculosis treatment, showing their efficacy comparable to isoniazid and their potential in new drug regimens.

bioRxiv · Mar 8, 2024 · PreprintPharmacology & Toxicology